Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study

Open access
Shore, Neal D., Boorjian, Stephen A., Canter, Daniel J., Ogan, Kenneth, Karsh, Lawrence I., Downs, Tracy M., Gomella, Leonard G., Kamat, Ashish M., Lotan, Yair, Svatek, Robert S., Bivalacqua, Trinity J., Grubb, Robert L., Krupski, Tracey L., Lerner, Seth P., Woods, Michael E., Inman, Brant A., Milowsky, Matthew I., Boyd, Alan, Treasure, F. Peter, Gregory, Gillian, Sawutz, David G., Yla-Herttuala, Seppo, Parker, Nigel R., Dinney, Colin P.N.·2017·Journal of Clinical Oncology

Abstract

Purpose: Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd–IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods: In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier: NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd–IFNα/Syn3 (randomly assigned 1:1 to 1 × 10 11 viral particles (vp)/mL or 3 × 10 11 vp/mL). Patients who responded at months 3, 6, and 9 were retreated at months 4, 7, and 10. The primary end point was 12-month HG recurrence-free survival (RFS). All patients who received at least one dose were included in efficacy and safety analyses. Results: Forty patients received rAd–IFNα/Syn3 (1 × 10 11 vp/mL, n = 21; 3 × 10 11 vp/mL, n = 19) between November 5, 2012, and April 8, 2015. Fourteen patients (35.0%; 90% CI, 22.6% to 49.2%) remained free of HG recurrence 12 months after initial treatment. Comparable 12-month HG RFS was noted for both doses. Of these 14 patients, two experienced recurrence at 21 and 28 months, respectively, after treatment initiation, and one died as a result of an upper tract tumor at 17 months without a recurrence. rAd–IFNα/Syn3 was well tolerated; no grade four or five adverse events (AEs) occurred, and no patient discontinued treatment because of an adverse event. The most frequently reported drug-related AEs were micturition urgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria (n = 11; 28%), and hematuria and nocturia (n = 10 each; 25%). Conclusion: rAd—IFNα/Syn3 was well tolerated. It demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who were unable or unwilling to undergo radical cystectomy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.72.3064

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 167

Metadata

Authors
Shore, N. D., Boorjian, S. A., Canter, D. J., Ogan, K., Karsh, L. I., Downs, T. M., Gomella, L. G., Kamat, A. M., Lotan, Y., Svatek, R. S., Bivalacqua, T. J., Grubb, R. L., Krupski, T. L., Lerner, S. P., Woods, M. E., Inman, B. A., Milowsky, M. I., Boyd, A., Treasure, F. P., Gregory, G., Sawutz, D. G., Yla-Herttuala, S., Parker, N. R., & Dinney, C. P. N.
Venue
Journal of Clinical Oncology
Published
2017-10-20
Volume
35
Issue
30
Pages
3410-3416
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2599812325
Cited by
167
References
1
FWCI
15.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. https://app.cochat.ai/papers/10.1200/jco.2017.72.3064
The paper
Shore, N. D., Boorjian, S. A., Canter, D. J., Ogan, K., Karsh, L. I., Downs, T. M., Gomella, L. G., Kamat, A. M., Lotan, Y., Svatek, R. S., Bivalacqua, T. J., Grubb, R. L., Krupski, T. L., Lerner, S. P., Woods, M. E., Inman, B. A., Milowsky, M. I., Boyd, A., Treasure, F. P., . . . Dinney, C. P. N. (2017). Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.72.3064

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.